ASX:BNO (Australia)
Business Description
Bionomics Ltd
SIC : 2836
200 Greenhill Road, Eastwood, SA, AUS, 5063
Compare
Compare
Traded in other countries / regions
BNO.Australia
•
B1N.Germany
•
BNOEF.USA
Description
Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 52.47 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | -0.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -100 | |||||
| 3-Year EBITDA Growth Rate | -100 | |||||
| 3-Year EPS without NRI Growth Rate | -100 | |||||
| 3-Year FCF Growth Rate | -15.4 | |||||
| 3-Year Book Growth Rate | -100 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.82 | |||||
| 9-Day RSI | 52.82 | |||||
| 14-Day RSI | 48.78 | |||||
| 6-1 Month Momentum % | -32.94 | |||||
| 12-1 Month Momentum % | -71.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.46 | |||||
| Quick Ratio | 13.46 | |||||
| Cash Ratio | 12.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -54.48 | |||||
| ROA % | -44.9 | |||||
| ROIC % | -78.43 | |||||
| ROC (Joel Greenblatt) % | -3056.11 | |||||
| ROCE % | -48.54 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.63 | |||||
| Price-to-Tangible-Book | 1.06 | |||||
| EV-to-Forward-EBIT | -1.19 | |||||
| EV-to-Forward-EBITDA | -1.19 | |||||
| EV-to-Forward-Revenue | 3.23 | |||||
| EV-to-FCF | -0.48 | |||||
| Price-to-Net-Current-Asset-Value | 1.06 | |||||
| Price-to-Net-Cash | 1.06 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 0 | ||
| EPS (TTM) (A$) | -0.033 | ||
| Beta | 2.34 | ||
| Volatility % | 50.75 | ||
| 14-Day RSI | 48.78 | ||
| 14-Day ATR (A$) | 0.003307 | ||
| 20-Day SMA (A$) | 0.052375 | ||
| 12-1 Month Momentum % | -71.5 | ||
| 52-Week Range (A$) | 0.044 - 0.205 | ||
| Shares Outstanding (Mil) | 1,353.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bionomics Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||